共 448 条
[1]
Luengo-Fernandez R(2013)Economic burden of cancer across the European Union: a population-based cost analysis Lancet Oncol. 14 1165-1174
[2]
Leal J(2017)Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers JAMA 317 2402-2416
[3]
Gray A(2011)Hereditary breast and ovarian cancer: new genes, new treatments, new concepts Dtsch. Arztebl. Int 108 323-330
[4]
Sullivan R(2018)Changes in classification of genetic variants in BRCA1 and BRCA2 Arch. Gynecol. Obstet. 297 279-280
[5]
Kuchenbaecker KB(2017)Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation Eur. J. Health Econ. 19 341-353
[6]
Hopper JL(2016)German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer J. Med. Genet. 53 465-471
[7]
Barnes DR(2015)Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and/or ovarian cancer J. Mol. Diagn. 17 162-170
[8]
Phillips KA(2001)Early breast cancer detection in Germany—knowledge and acceptance among the female population Dtsch. Arztebl. 98 A-2178/B-1849/C-1741-67
[9]
Mooij TM(2013)GEKID Cancer Survival Working Group. Survival of ovarian cancer patients in Germany in the early 21st century: a period analysis by age, histology, laterality, and stage Eur. J. Cancer Prev. 22 59-1020
[10]
Roos-Blom MJ(2012)Impact of comorbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990–2008 Breast Cancer Res. Treat. 131 1013-419